NCT01897571 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 14
- group Id
- BG004
- value
- 12
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 13
- group Id
- BG007
- value
- 48
- group Id
- BG008
- value
- 54
- group Id
- BG009
- value
- 163
- group Id
- BG010
- value
- 71
- group Id
- BG011
- value
- 400
- units
- Participants
- groups
- description
- Patients received tazemetostat 100 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.
- id
- BG000
- title
- Phase 1: Tazemetostat 100 mg
- description
- Patients received tazemetostat 200 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent
- id
- BG001
- title
- Phase 1: Tazemetostat 200 mg
- description
- Patients received tazemetostat 400 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.
- id
- BG002
- title
- Phase 1: Tazemetostat 400 mg
- description
- Patients received tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent
- id
- BG003
- title
- Phase 1: Tazemetostat 800 mg
- description
- Patients received tazemetostat 1600 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.
- id
- BG004
- title
- Phase 1: Tazemetostat 1600 mg
- description
- Patients received tazemetostat 200 mg as a single oral dose on Day -8 either after fasting for 8 hours before dosing or immediately after consuming a high-fat breakfast on Day -8. Following a 7-day washout period, patients crossed over to receive the second tazemetostat 200 mg single oral dose on Day -1 in the opposite condition (fed or fasted).
- id
- BG005
- title
- Phase 1: Food Effect (All Patients)
- description
- Patients received tazemetostat 800 mg orally BID continuously starting on Day 1, with a single oral dose of midazolam 2 mg administered on Day -1 and then on Day 15. Post Day 15, patients continued to receive tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.
- id
- BG006
- title
- Phase 1: Tazemetostat 800 mg + Midazolam 2 mg
- description
- Patients with R/R FL with mutant EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. Tazemetostat: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
- id
- BG007
- title
- Phase 2 Group 1: Tazemetostat in R/R FL With Mutant EZH2
- description
- Patients with R/R FL with wild-type EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. Tazemetostat: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
- id
- BG008
- title
- Phase 2 Group 2: Tazemetostat in R/R FL With Wild-Type EZH2
- description
- Patients with R/R DLBCL received 800 mg of tazemetostat monotherapy, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. Tazemetostat: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
- id
- BG009
- title
- Phase 2 Group 3: Tazemetostat in R/R DLBCL Monotherapy
- description
- Patients received tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. In addition, these patients also received prednisolone 40 mg/m\^2 on Days 1 to 5 and 15 to 19 from Cycle 1 to Cycle 4 post which tazemetostat monotherapy was continued.
- id
- BG010
- title
- Phase 2 Group 4: Tazemetostat + Prednisolone in R/R DLBCL Combination Therapy
- description
- Total of all reporting groups
- id
- BG011
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 15.74
- value
- 51.5
- group Id
- BG001
- spread
- 30.20
- value
- 55.0
- group Id
- BG002
- spread
- 7.00
- value
- 59.0
- group Id
- BG003
- spread
- 13.54
- value
- 56.4
- group Id
- BG004
- spread
- 21.42
- value
- 51.6
- group Id
- BG005
- spread
- 16.39
- value
- 53.2
- group Id
- BG006
- spread
- 13.66
- value
- 55.0
- group Id
- BG007
- spread
- 8.83
- value
- 62.0
- group Id
- BG008
- spread
- 11.38
- value
- 61.1
- group Id
- BG009
- spread
- 14.35
- value
- 63.2
- group Id
- BG010
- spread
- 11.78
- value
- 65.4
- group Id
- BG011
- spread
- 13.7
- value
- 61.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 26
- group Id
- BG008
- value
- 20
- group Id
- BG009
- value
- 72
- group Id
- BG010
- value
- 32
- group Id
- BG011
- value
- 176
- title
- Female
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 22
- group Id
- BG008
- value
- 34
- group Id
- BG009
- value
- 91
- group Id
- BG010
- value
- 39
- group Id
- BG011
- value
- 224
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 7
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 38
- group Id
- BG008
- value
- 26
- group Id
- BG009
- value
- 103
- group Id
- BG010
- value
- 62
- group Id
- BG011
- value
- 268
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 25
- group Id
- BG009
- value
- 57
- group Id
- BG010
- value
- 8
- group Id
- BG011
- value
- 125
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 5
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 33
- group Id
- BG008
- value
- 15
- group Id
- BG009
- value
- 71
- group Id
- BG010
- value
- 28
- group Id
- BG011
- value
- 186
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 15
- group Id
- BG008
- value
- 38
- group Id
- BG009
- value
- 89
- group Id
- BG010
- value
- 41
- group Id
- BG011
- value
- 208
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 14
- group Id
- BG004
- value
- 12
- group Id
- BG005
- value
- 13
- group Id
- BG006
- value
- 13
- group Id
- BG007
- value
- 48
- group Id
- BG008
- value
- 54
- group Id
- BG009
- value
- 163
- group Id
- BG010
- value
- 71
- group Id
- BG011
- value
- 400
- units
- Participants
- groups
- description
- Patients received tazemetostat 100 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.
- id
- BG000
- title
- Phase 1: Tazemetostat 100 mg
- description
- Patients received tazemetostat 200 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent
- id
- BG001
- title
- Phase 1: Tazemetostat 200 mg
- description
- Patients received tazemetostat 400 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.
- id
- BG002
- title
- Phase 1: Tazemetostat 400 mg
- description
- Patients received tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent
- id
- BG003
- title
- Phase 1: Tazemetostat 800 mg
- description
- Patients received tazemetostat 1600 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.
- id
- BG004
- title
- Phase 1: Tazemetostat 1600 mg
- description
- Patients received tazemetostat 200 mg as a single oral dose on Day -8 either after fasting for 8 hours before dosing or immediately after consuming a high-fat breakfast on Day -8. Following a 7-day washout period, patients crossed over to receive the second tazemetostat 200 mg single oral dose on Day -1 in the opposite condition (fed or fasted).
- id
- BG005
- title
- Phase 1: Food Effect (All Patients)
- description
- Patients received tazemetostat 800 mg orally BID continuously starting on Day 1, with a single oral dose of midazolam 2 mg administered on Day -1 and then on Day 15. Post Day 15, patients continued to receive tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent.
- id
- BG006
- title
- Phase 1: Tazemetostat 800 mg + Midazolam 2 mg
- description
- Patients with R/R FL with mutant EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. Tazemetostat: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
- id
- BG007
- title
- Phase 2 Group 1: Tazemetostat in R/R FL With Mutant EZH2
- description
- Patients with R/R FL with wild-type EZH2 treated with tazemetostat as a single agent in Phase 2 of the study. Patients received 800 mg of tazemetostat, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. Tazemetostat: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
- id
- BG008
- title
- Phase 2 Group 2: Tazemetostat in R/R FL With Wild-Type EZH2
- description
- Patients with R/R DLBCL received 800 mg of tazemetostat monotherapy, orally BID, administered in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. Tazemetostat: Patients who received 800 mg of tazemetostat, BID, administered in continuous 28-day cycles.
- id
- BG009
- title
- Phase 2 Group 3: Tazemetostat in R/R DLBCL Monotherapy
- description
- Patients received tazemetostat 800 mg tablets orally BID in continuous 28-day treatment cycles until confirmed disease progression, unacceptable toxicity, or withdrawal of consent. In addition, these patients also received prednisolone 40 mg/m\^2 on Days 1 to 5 and 15 to 19 from Cycle 1 to Cycle 4 post which tazemetostat monotherapy was continued.
- id
- BG010
- title
- Phase 2 Group 4: Tazemetostat + Prednisolone in R/R DLBCL Combination Therapy
- description
- Total of all reporting groups
- id
- BG011
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 15.74
- value
- 51.5
- group Id
- BG001
- spread
- 30.20
- value
- 55.0
- group Id
- BG002
- spread
- 7.00
- value
- 59.0
- group Id
- BG003
- spread
- 13.54
- value
- 56.4
- group Id
- BG004
- spread
- 21.42
- value
- 51.6
- group Id
- BG005
- spread
- 16.39
- value
- 53.2
- group Id
- BG006
- spread
- 13.66
- value
- 55.0
- group Id
- BG007
- spread
- 8.83
- value
- 62.0
- group Id
- BG008
- spread
- 11.38
- value
- 61.1
- group Id
- BG009
- spread
- 14.35
- value
- 63.2
- group Id
- BG010
- spread
- 11.78
- value
- 65.4
- group Id
- BG011
- spread
- 13.7
- value
- 61.7
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 7
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 26
- group Id
- BG008
- value
- 20
- group Id
- BG009
- value
- 72
- group Id
- BG010
- value
- 32
- group Id
- BG011
- value
- 176
- title
- Female
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 22
- group Id
- BG008
- value
- 34
- group Id
- BG009
- value
- 91
- group Id
- BG010
- value
- 39
- group Id
- BG011
- value
- 224
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 3
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 7
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 38
- group Id
- BG008
- value
- 26
- group Id
- BG009
- value
- 103
- group Id
- BG010
- value
- 62
- group Id
- BG011
- value
- 268
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 25
- group Id
- BG009
- value
- 57
- group Id
- BG010
- value
- 8
- group Id
- BG011
- value
- 125
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- calculate Pct
- false
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 1
- group Id
- BG009
- value
- 3
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 5
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 1
- group Id
- BG011
- value
- 1
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 11
- group Id
- BG007
- value
- 33
- group Id
- BG008
- value
- 15
- group Id
- BG009
- value
- 71
- group Id
- BG010
- value
- 28
- group Id
- BG011
- value
- 186
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- group Id
- BG009
- value
- 0
- group Id
- BG010
- value
- 0
- group Id
- BG011
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 2
- group Id
- BG007
- value
- 15
- group Id
- BG008
- value
- 38
- group Id
- BG009
- value
- 89
- group Id
- BG010
- value
- 41
- group Id
- BG011
- value
- 208
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle